{"id":22615,"date":"2026-11-16T10:31:56","date_gmt":"2026-11-16T10:31:56","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&#038;p=22615"},"modified":"2026-11-16T14:17:09","modified_gmt":"2026-11-16T14:17:09","slug":"exceptionally-stable-wild-type-alpha-synuclein","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/","title":{"rendered":"Exceptionally stable wild type alpha synuclein"},"content":{"rendered":"\n<h2 id=\"h-we-are-excited-to-present-our-ability-to-produce-large-up-to-350-mg-batches-of-high-quality-monomeric-wild-type-human-alpha-synuclein-\u03b1syn-protein-our-\u03b1syn-has-excellent-batch-to-batch-reproducibility-that-displays-no-self-seeding-in-seed-aggregation-assays-saas-including-real-time-quaking-induced-conversion-rt-quic-assays-enabling-reliable-analysis-of-csf-samples\" class=\"wp-block-heading has-dark-blue-700-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-1\"><strong>We are excited to present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To support these claims, data from Sygnature\u2019s internal team and two world-renowned SAA-expert laboratories are presented below.<\/p>\n\n\n\n<p class=\"has-blue-600-color has-text-color has-link-color wp-elements-2 wp-block-paragraph\"><strong>To discuss your particular requirements and to get a quote for a custom batch of<\/strong> <strong>\u03b1Syn please get in touch<\/strong>.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\" style=\"padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-button\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/contact\/\">Contact Us<\/a><\/div>\n<\/div>\n\n\n\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--1\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"508\" height=\"355\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-1-Purified-aSyn.webp\" alt=\"SDS PAGE of 3 different batches of aSyn produced at Sygnature Discovery\" class=\"wp-image-22618\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-1-Purified-aSyn.webp 508w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-1-Purified-aSyn-300x210.webp 300w\" sizes=\"(max-width: 508px) 100vw, 508px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 1: <\/strong>Reduced SDS PAGE of three separate \u03b1Syn batches (A \u2013 C) produced at Sygnature Discovery. Note, the \u03b1Syn tends to run higher than its actual 14kDa with respect to the molecular weight markers in the first lane.<\/em> <\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Some lower molecular weight species are typically observed, and occasionally higher molecular weight species are present (e.g Figure 1 C). Neither impact performance in SAAs.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\" style=\"padding-top:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--40)\">\n<div class=\"wp-block-button\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Sygnature-Wild-Type-human-aSyn-Example-QC-data-sheet.pdf\" target=\"_blank\" rel=\"noopener\">Download an example data sheet here<\/a><\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\">We are also able to produce various mutant versions of \u03b1Syn (Figure 2).<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--2\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"299\" height=\"276\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-2-aSyn-mutants-that-are-available.webp\" alt=\"Table of mutant versions of aSyn that are available\" class=\"wp-image-22619\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 2:<\/strong> Portfolio of available \u03b1Syn variants (based on wild-type UniProt P37840). All are produced in E. coli, purified to the same high standard, and supplied without affinity tags. Other mutants or tagged versions can be discussed upon request.<\/em><\/figcaption><\/figure>\n\n\n\n<h3 id=\"h-background-to-\u03b1syn\" class=\"wp-block-heading has-dark-blue-700-color has-text-color has-link-color has-text-lg-font-size wp-elements-3\"><strong>Background to \u03b1Syn<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">As both a therapeutic target and a key biomarker, \u03b1-synuclein (\u03b1Syn) sits at the center of efforts to better understand, diagnose and treat neurodegenerative disorders. Its involvement in diseases such as Parkinson\u2019s disease and Dementia with Lewy bodies (DLB) has made \u03b1Syn a major focus for drug discovery, biomarker development and translational research.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under normal conditions, \u03b1Syn is a small, intrinsically disordered 14 kDa protein found in neurons. In Parkinson\u2019s disease and related synucleinopathies, however, \u03b1Syn can misfold and aggregate into the characteristic fibrils associated with neuronal dysfunction and cell death. For an overview of \u03b1Syn protein and its role in disease, please refer to our mini review article <a href=\"https:\/\/www.sygnaturediscovery.com\/blog\/alpha-synuclein-an-intriguing-little-protein-mini-review\/\" target=\"_blank\" rel=\"noreferrer noopener\">here.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As interest in \u03b1Syn-based therapeutics and diagnostic approaches continues to grow, access to high-quality, well-characterized \u03b1Syn reagents has become increasingly important.<\/p>\n\n\n\n<h3 id=\"h-the-challenge\" class=\"wp-block-heading has-dark-blue-700-color has-text-color has-link-color has-text-lg-font-size wp-elements-4\"><strong>The Challenge<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Production of highly pure, stable monomeric \u03b1Syn protein (Uniprot P37840) to support SAAs, which include the Real-Time Quaking-Induced Conversion (RT-QuIC) assays, has proved to be incredibly difficult to achieve. The requirements for the \u03b1Syn to support these assays are that it should be:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Monomeric<\/li>\n\n\n\n<li>Stable, and does not self-seed or self-aggregate throughout the time course of the assay<\/li>\n\n\n\n<li>Gives a good signal window in SAAs that allows clear discrimination of patient test samples that either contain or do not contain pathological \u03b1Syn<\/li>\n\n\n\n<li>Has consistent batch-to-batch performance in SAAs<\/li>\n\n\n\n<li>Ideally large (&gt;100mg) batches of purified protein<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Although \u03b1Syn is available from multiple commercial suppliers, researchers continue to report batch-to-batch variability that can compromise the consistency and reliability of data from SAAs. Indeed, Oliviera et al., 2026 from The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) made this statement:<\/p>\n\n\n\n<p class=\"has-white-color has-dark-blue-700-background-color has-text-color has-background has-link-color wp-elements-5 wp-block-paragraph\" style=\"border-top-left-radius:24px;border-top-right-radius:24px;border-bottom-left-radius:24px;border-bottom-right-radius:24px\"><em>\u00ab\u00a0Furthermore, commercially available aSyn proteins yielded inconsistent and suboptimal results, and scaling up production posed significant technical and logistical challenges. In response, MJFF launched a large-scale effort to develop affordable, high-quality, commercially available aSyn SAA substrate through a precompetitive collaboration across industry, protein manufacturers, academic SAA experts, and commercial distributors\u2013 all for the benefit of the broader research community\u00a0\u00bb<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Producing high-quality recombinant \u03b1Syn is particularly challenging because the protein can undergo non-specific conversion and aggregation if not carefully handled and controlled during purification.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We have observed cases where a recombinant \u03b1Syn preparation looked pure on SDS PAGE gel, had the exact expected mass on intact mass spectrometry (with no contaminant peaks or modifications), was monomeric on analytical size-exclusion chromatography with multi-angle light scattering (SEC-MALS) and Flow Induced Dispersion Analysis (FIDA), yet obviously still contained, undetectable trace levels of oligomeric \u03b1Syn that were unfortunately sufficient to initiate self-seeding in an RT-QuIC assay (Figure 3).<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--3\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"429\" height=\"307\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-3-RTQuIC-showing-spontaneous-aggregation-of-aSyn.webp\" alt=\"RTQuIC assay showing spontaneous aggregation of aSyn\" class=\"wp-image-22688\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-3-RTQuIC-showing-spontaneous-aggregation-of-aSyn.webp 429w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-3-RTQuIC-showing-spontaneous-aggregation-of-aSyn-300x215.webp 300w\" sizes=\"(max-width: 429px) 100vw, 429px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 3: <\/strong>RT-QuIC assay data (repeats of 3 spiked and 8 unspiked control runs) with a poor batch of \u03b1Syn substrate that displays spontaneous aggregation in unspiked control (grey) even though a good signal is still observed with DLB Brain homogenate (blue).<\/em><\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Detection of these undesired oligomers is impossible with current biophysical techniques, the only true test being validation in the end use SAA or desired application. This purification challenge is discussed in Stephens et al., 2020 with one solution presented by Al-Azzawi et al., 2025 to purify \u03b1Syn from the periplasmic fraction. However, this periplasmic route is not optimal as a method to produce the large amounts of \u03b1Syn generally required to support RT-QuIC assays.<\/p>\n\n\n\n<h3 id=\"h-our-solution\" class=\"wp-block-heading has-dark-blue-700-color has-text-color has-link-color has-text-lg-font-size wp-elements-6\"><strong>Our Solution<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Production of monomeric wild type human alpha synuclein<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Within the Protein and Structure department at Sygnature Discovery, we have been purifying wild type and mutant versions of \u03b1Syn for different clients for several years, using either <em>E. coli<\/em> or mammalian expression hosts, and a variety of purification protocols. Our clients routinely return for resupplies for their assays which is a testament to the quality and batch-to-batch consistency of the \u03b1Syn we produce.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Building on this experience, for the last few years we have been running a project supported by The MJFF to optimize the production of monomeric wild type human \u03b1Syn. The ultimate goal of the project is to produce large (\u22654 gram) batches of \u03b1Syn to make available as a global resource to reduce variability in data obtained between groups working on Parkinsons Disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">During this project we have run hundreds of experiments to refine cell culture and protein purification protocols. In order to validate and to confirm that the \u03b1Syn produced is fit for purpose the trial batches have been tested in RT-QuIC assays by Christina Orru in the Caughey lab at the NIH\/NIAID and Graham Fairfoul in the Barria (formerly Green) lab at The University of Edinburgh.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--4\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"766\" height=\"440\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp\" alt=\"Project partners for the monomeric aSyn production project\" class=\"wp-image-22687\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp 766w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners-300x172.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners-627x360.webp 627w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners-640x368.webp 640w\" sizes=\"(max-width: 766px) 100vw, 766px\"><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">To address the challenges associated with producing reliable \u03b1Syn reagents, Sygnature Discovery has developed a robust expression and purification process for wild-type human \u03b1Syn in <em>E. coli<\/em>. This process routinely delivers:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Up to 350mg batches of \u03b1Syn<\/li>\n\n\n\n<li>&gt;90% pure protein \u2013 Figure 1 (however our data suggests that purity is NOT critical for performance in RT-QuIC assays)<\/li>\n\n\n\n<li>Consistent batch-to-batch reproducibility in terms of yield, purity and most importantly performance in RT-QuIC assays<\/li>\n\n\n\n<li>\u03b1Syn with remarkable stability in RT-QuIC assays (\u2265150 hours showing no spontaneous self-aggregation) \u2013 Figure 4 a to c<\/li>\n\n\n\n<li>Excellent assay windows in RT-QuIC assays with challenging patient-derived samples \u2013 Figure 4 a to c<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large is-style-rounded is-style-rounded--5\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"340\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4a-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1024x340.webp\" alt=\"RTQuIC Data With ASyn Showing No Spontaneous Aggregation\" class=\"wp-image-22689\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4a-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1024x340.webp 1024w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4a-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-300x100.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4a-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-768x255.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4a-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-640x213.webp 640w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4a-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation.webp 1204w\" sizes=\"(max-width: 1024px) 100vw, 1024px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 4a:<\/strong> RT-QuIC assay data (each in triplicate) performed by the NIH\/NIAID with \u03b1Syn negative control (left) CBD (Corticobasal degeneration) brain homogenates (BH) showing no spontaneous seeding with \u03b1Syn &gt;150 hours, (right) rapid amplification of aggregated \u03b1Syn from a DLB (Dementia with Lewy bodies) brain homogenates (BH) sample and overall good discrimination between a \u03b1Syn-negative and -positive brain sample.<\/em><\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large is-style-rounded is-style-rounded--6\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"288\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4b-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1-1024x288.webp\" alt=\"RTQuIC Data With ASyn Showing No Spontaneous Aggregation\" class=\"wp-image-22690\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4b-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1-1024x288.webp 1024w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4b-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1-300x84.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4b-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1-768x216.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4b-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1-640x180.webp 640w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4b-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1.webp 1108w\" sizes=\"(max-width: 1024px) 100vw, 1024px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 4b:<\/strong> RT-QuIC assay data (each in triplicate) performed by the NIH\/NIAID with negative Cerebral Spinal Fluid (CSF) control (left) showing no spontaneous seeding with \u03b1Syn &gt;50 hours and (middle) a rapid detection of low levels of aggregated \u03b1Syn in CSF spiked with a Parkinsons Disease patient (PD) Brain Homogenate and (right) with DLB Brain homogenate.<\/em><\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large is-style-rounded is-style-rounded--7\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"297\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4c-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1024x297.webp\" alt=\"RTQuIC Data With ASyn Showing No Spontaneous Aggregation\" class=\"wp-image-22691\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4c-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-1024x297.webp 1024w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4c-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-300x87.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4c-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-768x223.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4c-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation-640x186.webp 640w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-4c-RTQuIC-data-with-aSyn-showing-no-spontaneous-aggregation.webp 1223w\" sizes=\"(max-width: 1024px) 100vw, 1024px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 4c: <\/strong>RT-QuIC assay data performed by the University of Edinburgh with DLB Brain homogenate (blue) and unspiked control (grey) and with unspiked artificial CSF control (green) and spiked artificial CSF (yellow). Both experiments show no spontaneous aggregation of the \u03b1Syn in the control unspiked experiments over 120 hours (grey and green) and then excellent ThT fluorescence assay signal with the spiked samples (blue and yellow).<\/em><\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Figure 4 a-c data was presented by Polinski et al., 2025 at the AD\/PD conference.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In addition, based on the protocols described in Polinski et al., 2018, we have produced Pre-Formed Fibrils (PFFs) using our in-house \u03b1Syn to test and compare various batches of monomeric \u03b1Syn. Figure 5 and 6<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-style-rounded is-style-rounded--8\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"372\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-SAA-with-in-house-PFFs-1024x372.webp\" alt=\"SAA With In House PFFs\" class=\"wp-image-22692\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-SAA-with-in-house-PFFs-1024x372.webp 1024w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-SAA-with-in-house-PFFs-300x109.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-SAA-with-in-house-PFFs-768x279.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-SAA-with-in-house-PFFs-640x233.webp 640w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-SAA-with-in-house-PFFs.webp 1097w\" sizes=\"(max-width: 1024px) 100vw, 1024px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 5: <\/strong>Seed aggregation assay with in-house \u03b1Syn PFFs. Left: monomers only \u2013 no self aggregation of 8 separate batches \u03b1Syn observed over 50 hours. Right: monomers with 8 separate batches of \u03b1Syn \u2013 all displaying good aggregation signal with ThT<\/em><\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full is-style-rounded is-style-rounded--9\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"449\" height=\"336\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-6-SAA-with-in-house-PFFs-and-3-batches-of-aSyn.webp\" alt=\"SAA With In House PFFs And 3 Batches Of ASyn\" class=\"wp-image-22693\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-6-SAA-with-in-house-PFFs-and-3-batches-of-aSyn.webp 449w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-6-SAA-with-in-house-PFFs-and-3-batches-of-aSyn-300x224.webp 300w\" sizes=\"(max-width: 449px) 100vw, 449px\"><figcaption class=\"wp-element-caption\"><em><strong>Figure 6:<\/strong> Seed aggregation assay with in-house \u03b1Syn PFFs and 3 different batches of monomeric \u03b1Syn.<\/em><\/figcaption><\/figure>\n\n\n\n<h3 id=\"h-in-summary\" class=\"wp-block-heading has-dark-blue-700-color has-text-color has-link-color has-text-lg-font-size wp-elements-7\"><strong>In Summary<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">At Sygnature Discovery, we support Parkinson\u2019s disease and broader synucleinopathy research with the production of high-quality recombinant \u03b1Syn for Seed Aggregation Assays (SAAs), including RT-QuIC, PFF production, drug screening and other end use applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We routinely produce large (up to 350mg) batches of high quality monomeric, wild-type, human alpha synuclein (\u03b1Syn) protein with the quality, consistency and performance required for demanding assay applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If required, we also have experience producing<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>mutant or tagged forms of \u03b1Syn<\/li>\n\n\n\n<li>Other proteins involved in neurodegenerative diseases<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Whether you are developing diagnostics, investigating disease mechanisms, or advancing novel Parkinson\u2019s disease therapeutics, our team can help provide the \u03b1Syn reagents needed to support your research. Please don\u2019t hesitate to get in touch to discuss your project requirements.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\" style=\"padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-button\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/contact\/\">Contact Us<\/a><\/div>\n<\/div>\n\n\n\n<h3 id=\"h-references\" class=\"wp-block-heading has-dark-blue-700-color has-text-color has-link-color has-text-lg-font-size wp-elements-8\"><strong>References<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Al-Azzawi, Z. A. M., Silver, N. R. G., Mehra, S., Niu, S., Situ, C., Luo, W., Shlaifer, I., Ingelsson, M., Hyman, B. T., Trempe, J.-F., Durcan, T. M., Watts, J. C., &amp; Fon, E. A. (2025). \u03b1-Synuclein purification significantly impacts seed amplification assay performance and consistency. <em>Acta Neuropathologica Communications<\/em>, <em>13<\/em>(1), 225. https:\/\/doi.org\/10.1186\/s40478-025-02151-4<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Polinski, N. K., Volpicelli-Daley, L. A., Sortwell, C. E., Luk, K. C., Cremades, N., Gottler, L. M., Froula, J., Duffy, M. F., Lee, V. M. Y., Martinez, T. N., &amp; Dave, K. D. (2018). Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson\u2019s Disease in Rodents. <em>Journal of Parkinson\u2019s Disease<\/em>, <em>8<\/em>(2), 303\u2013322. https:\/\/doi.org\/10.3233\/JPD-171248<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Stephens, A. D., Matak-Vinkovic, D., Fernandez-Villegas, A., &amp; Kaminski Schierle, G. S. (2020). Purification of Recombinant \u03b1-synuclein: A Comparison of Commonly Used Protocols. <em>Biochemistry<\/em>, <em>59<\/em>(48), 4563\u20134572. https:\/\/doi.org\/10.1021\/acs.biochem.0c00725<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Oliveira, L. M. A., Frasier, M., Hutten, S, J. (2026). Collaborative action for biomarker breakthroughs: Validating \u03b1-synuclein seed amplification assays in Parkinson\u2019s disease. <em>Journal of Parkinson\u2019s Disease<\/em>, Special Issue: Open Science in Parkinson\u2019s Research, 1 \u2013 7. <a href=\"https:\/\/doi.org\/10.1177\/1877718X261431949\">https:\/\/doi.org\/10.1177\/1877718X261431949<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nicole K. Polinski, Richard Mott, Anna Valentine, Graham Fairfoul, Marcelo Barria Matus, Alison Green, Christina D Orr\u00fa, Byron Caughey, Jonathan Jones,Panos Kopsiaftis, Matthew Biggs, Robert Cleverley, Zoe Arnott, Elisia Clark, Gloria Thakuria, Jamie Eberling (2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Michael J. Fox Foundation\u2019s efforts to develop specialized alpha-synuclein monomeric protein for the alpha-synuclein seed amplification assay<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Poster presented at the AD\/PD 2025 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":22687,"template":"","category":[753,680,702],"resource_tag":[1404,660],"class_list":["post-22615","case-study","type-case-study","status-publish","has-post-thumbnail","hentry","category-neuroscience","category-protein-and-structure","category-protein-expression-and-purification","resource_tag-protein-and-structure","resource_tag-protein-purification"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.8 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Exceptionally stable wild type alpha synuclein - Sygnature<\/title>\n<meta name=\"description\" content=\"In this case study we present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exceptionally stable wild type alpha synuclein\" \/>\n<meta property=\"og:description\" content=\"In this case study we present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T14:17:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"766\" \/>\n\t<meta property=\"og:image:height\" content=\"440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/\",\"name\":\"Exceptionally stable wild type alpha synuclein - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/aSyn-Project-Partners.webp\",\"datePublished\":\"2026-11-16T10:31:56+00:00\",\"dateModified\":\"2026-11-16T14:17:09+00:00\",\"description\":\"In this case study we present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/aSyn-Project-Partners.webp\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/aSyn-Project-Partners.webp\",\"width\":766,\"height\":440,\"caption\":\"Project partners for the monomeric aSyn production project\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/exceptionally-stable-wild-type-alpha-synuclein\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exceptionally stable wild type alpha synuclein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exceptionally stable wild type alpha synuclein - Sygnature","description":"In this case study we present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/","og_locale":"fr_CA","og_type":"article","og_title":"Exceptionally stable wild type alpha synuclein","og_description":"In this case study we present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/","og_site_name":"Sygnature","article_modified_time":"2026-11-16T14:17:09+00:00","og_image":[{"width":766,"height":440,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/","name":"Exceptionally stable wild type alpha synuclein - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp","datePublished":"2026-11-16T10:31:56+00:00","dateModified":"2026-11-16T14:17:09+00:00","description":"In this case study we present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (\u03b1Syn) protein. Our \u03b1Syn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/aSyn-Project-Partners.webp","width":766,"height":440,"caption":"Project partners for the monomeric aSyn production project"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/exceptionally-stable-wild-type-alpha-synuclein\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Exceptionally stable wild type alpha synuclein"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/22615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/case-study"}],"version-history":[{"count":19,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/22615\/revisions"}],"predecessor-version":[{"id":22732,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/22615\/revisions\/22732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/22687"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=22615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=22615"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=22615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}